![]() | |
Clinical data | |
---|---|
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C31H27F2N5O3S2 |
Molar mass | 619.71 g·mol−1 |
3D model (JSmol) | |
| |
|
Glesatinib (MGCD265) is an experimental anti-cancer drug.[1][2]
It is in phase 2 clinical trials for non-small cell lung cancer (NSCLC).[3]
It is a spectrum selective tyrosine[1] kinase inhibitor "for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET".[4]
![]() | This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |